A clinical trial involving desmopressin was updated on September 25, 2026. The study, titled "Prophylactic Desmopressin Before Native Kidney Biopsy in Severe Renal Impairment," has reached completed status. The trial is registered under identifier NCT07840313 and is listed with a phase designation of not applicable.
The study examined the use of desmopressin given ahead of native kidney biopsy procedures in patients with severe renal impairment. Its listing on ClinicalTrials.gov now reflects a completed status as of the update date.
No results, outcomes, or efficacy conclusions have been provided alongside this status change. The completion designation indicates the trial has concluded its planned activities, but it does not by itself confirm what, if any, findings were reported. Readers should not interpret this update as evidence of benefit or risk related to desmopressin use in this setting.
Desmopressin remains an approved compound with established uses outside of this specific investigational context. This trial update pertains only to its evaluation in the described prophylactic biopsy setting.
Those interested in learning more about desmopressin generally can consult the compound overview for additional background and context.